Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, combined with special treatment (such as endoscopic sclerotherapy). 2. Prevent complications after pancreatic surgery. 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagon tumors. The efficacy of this product for the following tumors is about 50% (so far, the cases treated with this product are limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, growth hormone releasing factor tumor. 4. It can control symptoms and reduce the concentration of growth hormone (GH) and growth hormone mediator C in patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists. It is also suitable for patients with acromegaly who cannot or do not want to undergo surgery, and patients in the interval period when radiotherapy has not yet taken effect.

Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, used in combination with special treatments (such as endoscopic sclerotherapy). 2. Prevention of complications after pancreatic surgery. 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagonomas. The efficacy of this product for the following tumors is about 50% (the number of cases treated with this product so far is limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, and growth hormone releasing factor tumor. 4. It can control symptoms and reduce the concentration of growth hormone (GH) and growth hormone mediator C in patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists. It is also suitable for patients who cannot or do not

Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, used in combination with special treatments (such as endoscopic sclerotherapy). 2. Prevention of complications after pancreatic surgery. 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagonomas. The efficacy of this product for the following tumors is about 50% (the number of cases treated with this product so far is limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, and growth hormone releasing factor tumor. 4. It can control symptoms and reduce the concentration of growth hormone (GH) and growth hormone mediator C in patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists. It is also suitable for patients who cannot or do not

Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, combined with special treatment (such as endoscopic sclerotherapy). 2. Prevent complications after pancreatic surgery. 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagon tumors. The efficacy of this product for the following tumors is about 50% (so far, the cases treated with this product are limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, growth hormone releasing factor tumor. 4. It can control symptoms and reduce the concentration of growth hormone (GH) and growth hormone mediator C in patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists. It is also suitable for patients with acromegaly who cannot or do not want to undergo surgery, and patients in the interval period when radiotherapy has not yet taken effect.

Indication: 1. Active acromegaly, including patients whose serum GH level does not reach normal level after surgery for pituitary GH tumors, and after external pituitary irradiation radiotherapy. 2. Patients whose serum GH level is still elevated before the full therapeutic effect is achieved, and before surgery for pituitary tumors in some cases. 3. Severe diarrhea, flushing, electrolyte imbalance, exudative polymorphic rash caused by gastrointestinal neuroendocrine tumors and carcinoid syndrome, and AIDS-related diarrhea.

Indication: 1. Active acromegaly, including patients whose serum GH level does not reach normal level after surgery for pituitary GH tumors, and after external pituitary irradiation radiotherapy. 2. Patients whose serum GH level is still elevated before the full therapeutic effect is achieved, and before surgery for pituitary tumors in some cases. 3. Severe diarrhea, flushing, electrolyte imbalance, exudative polymorphic rash caused by gastrointestinal neuroendocrine tumors and carcinoid syndrome, and AIDS-related diarrhea.

Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, combined with special treatments (such as endoscopic sclerotherapy); 2. Prevention of complications after pancreatic surgery; 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagon tumors. The efficacy of this product for the following tumors is about 50% (so far, the number of cases treated with this product is limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, growth hormone releasing factor tumor; 4. Patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists.

Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, combined with special treatments (such as endoscopic sclerotherapy); 2. Prevention of complications after pancreatic surgery; 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagonomas. The efficacy of this product for the following tumors is about 50% (so far, the number of cases treated with this product is limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, growth hormone releasing factor tumor; 4. It can control symptoms and reduce the concentration of growth hormone (GH) and growth hormone mediator C in patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists. It is also suitable for patients who are not

Indication: 1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, used in combination with special treatments (such as endoscopic sclerotherapy). 2. Prevention of complications after pancreatic surgery. 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagonomas. The efficacy of this product for the following tumors is about 50% (so far, the number of cases treated with this product is limited); gastrinoma/Zollinger-Ellison syndrome, insulinoma, growth hormone releasing factor tumor. 4. It can control symptoms and reduce the concentrations of growth hormone (GH) and growth hormone mediator C in patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists. It is also suitable for

Indication: Digestive system medications. Esophageal gastric venous bleeding, peptic ulcer and emergency ulcer, acute pancreatitis, prevention of complications after pancreatic surgery, gastrointestinal pancreatic endocrine tumors, acromegaly.